Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.77 |
| ▸ | THRB | P10828 | 7/20 | 0.77 |
| ▸ | BLM | P54132 | 7/20 | 0.77 |
| ▸ | RECQL | P46063 | 6/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.77 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.77 |
| ▸ | TOP2A | P11388 | 5/20 | 0.77 |
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.77 |
| ▸ | STAT6 | P42226 | 4/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.77 |
| ▸ | HTT | P42858 | 3/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18071933 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL20427942 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL18751652 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL14341789 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL12368761 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL10452484 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL18751207 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL18751205 | 0.95 | MEN1 (0.73) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL14703485 | 0.95 | MEN1 (0.73) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL14706187 | 0.95 | MEN1 (0.73) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9707300-B2 | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites | IMMUNOMEDICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150196573-A1 | PROCESS FOR PRODUCING AN INJECTABLE MEDICAMENT PREPARATION | Vergell Medical S.A. (CH) | 2015-07-16 | — | — | US | disclosed |
| US-20150038686-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | IMMUNOMEDICS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8889835-B2 | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites | IMMUNOMEDICS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130072659-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | IMMUNOMEDICS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8338140-B2 | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites | IMMUNOMEDICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8153581-B2 | Process for producing an injectable medicament preparation | KTB TUMORFORSCHUNGS GMBH (DE) | 2012-04-10 | — | — | US | disclosed |
| US-8153581-B2 | Process for producing an injectable medicament preparation | KTB TUMORFORSCHUNGS GMBH (DE) | 2012-04-10 | — | — | US | disclosed |
| US-20120040431-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | IMMUNOMEDICS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8067006-B2 | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites | IMMUNOMEDICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067006-B2 | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites | IMMUNOMEDICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100233779-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | IMMUNOMEDICS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100215574-A1 | PROCESS FOR PRODUCING AN INJECTABLE MEDICAMENT PREPARATION | Vergell Medical S.A. (CH) | 2010-08-26 | — | — | US | disclosed |
| US-20100215574-A1 | PROCESS FOR PRODUCING AN INJECTABLE MEDICAMENT PREPARATION | Vergell Medical S.A. (CH) | 2010-08-26 | — | — | US | disclosed |
| US-20080171067-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | IMMUNOMEDICS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-7387771-B1 | dissolving in carrier liquid; drug linked to a protein-binding molecule via a spacer which is cleaved hydrolytically or enzymatically in the body of a subject in a pH-dependent manner; tissue targeted delivery; Doxorubicin-phenylacetylhydrazone spacer-maleimide | KTB TUMORFORSCHUNGS GMBH (DE) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040431-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | CD47, BSG, SELPLG | MEN1 899/4885KMT2A 1894/4885THRB 2726/4885 |
| US-20130072659-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | CD47, BSG, SELPLG | MEN1 899/4885KMT2A 1894/4885THRB 2726/4885 |
| US-20150038686-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | CD47, BSG, SELPLG | MEN1 899/4885KMT2A 1894/4885THRB 2726/4885 |
| US-20080171067-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | CD47, BSG, SELPLG | MEN1 899/4885KMT2A 1894/4885THRB 2726/4885 |
| US-20150196573-A1 | PROCESS FOR PRODUCING AN INJECTABLE MEDICAMENT PREPARATION | MMP1, MMP2, DNPEP | MEN1 1234/4885KMT2A 4845/4885THRB 3223/4885 |
| US-20100215574-A1 | PROCESS FOR PRODUCING AN INJECTABLE MEDICAMENT PREPARATION | MMP1, MMP2, DNPEP | MEN1 1234/4885KMT2A 4845/4885THRB 3223/4885 |
| US-20100233779-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | CD47, BSG, SELPLG | MEN1 899/4885KMT2A 1894/4885THRB 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.